Abstract
Hepatocyte growth factor (HGF) is a known angiogenic factor that has profound effects on vascular endothelial cells. In recent years, it has been reported that the factor also acts as a lymphagiogenic factor that induces lymphangenesis from lymphatic endothelial cells. The current article debates some of the recent evidence showing such an effect and also discusses the clinical studies that link to lymphatic related conditions, together with clinical implications. Keywords: Hepatocyte growth factor, lymphangiogenesis, endothelial cells, VEGF, melanoma, cMET, lymph node metastases, prostate cancer, lymphatic invasion, metastasis, squamous cell carcinoma, lymphatic microvessel density, LYVE-1, Prox-1, VEGF-R3, breast cancer, HGF antagonist, in vivo tumour models, D2-40 antibody, MW 40K, ERK, akt, PECAM
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
